These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34915595)

  • 1. Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD-L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment.
    Hei Y; Chen Y; Li Q; Mei Z; Pan J; Zhang S; Xiong C; Su X; Wei S
    Small; 2022 Mar; 18(9):e2105118. PubMed ID: 34915595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.
    Hei Y; Teng B; Zeng Z; Zhang S; Li Q; Pan J; Luo Z; Xiong C; Wei S
    Int J Nanomedicine; 2020; 15():1677-1691. PubMed ID: 32214807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.
    Peng Q; Zhu X; Li C; Xin P; Zheng Y; Liu S
    Aging (Albany NY); 2021 Feb; 13(5):7199-7210. PubMed ID: 33653969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy.
    Chen Q; Chen G; Chen J; Shen J; Zhang X; Wang J; Chan A; Gu Z
    Nano Lett; 2019 Aug; 19(8):4879-4889. PubMed ID: 31294571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
    Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
    Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmable melanoma-targeted radio-immunotherapy via fusogenic liposomes functionalized with multivariate-gated aptamer assemblies.
    Ren X; Xue R; Luo Y; Wang S; Ge X; Yao X; Li L; Min J; Li M; Luo Z; Wang F
    Nat Commun; 2024 Jun; 15(1):5035. PubMed ID: 38866788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects.
    Xie S; Hou X; Yang W; Shi W; Yang X; Duan S; Mo F; Liu A; Wang W; Lu X
    Int J Nanomedicine; 2021; 16():6017-6034. PubMed ID: 34511903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
    Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
    J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
    Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
    Lu L; Zhang H; Zhou Y; Lin J; Gao W; Yang T; Jin J; Zhang L; Nagle DG; Zhang W; Wu Y; Chen H; Luan X
    Theranostics; 2022; 12(7):3456-3473. PubMed ID: 35547769
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment.
    Kuo CL; Chou HY; Lien HW; Yeh CA; Wang JR; Chen CH; Fan CC; Hsu CP; Kao TY; Ko TM; Lee AY
    Cancer Immunol Immunother; 2023 Feb; 72(2):351-369. PubMed ID: 35895109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy.
    Dong Q; Han D; Li B; Yang Y; Ren L; Xiao T; Zhang J; Li Z; Yang H; Liu H
    Int J Biol Macromol; 2023 Jun; 240():124342. PubMed ID: 37030459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
    Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
    Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet Pharmacytes for the Hierarchical Amplification of Antitumor Immunity in Response to Self-Generated Immune Signals.
    Yan J; Liu X; Wu F; Ge C; Ye H; Chen X; Wei Y; Zhou R; Duan S; Zhu R; Zheng Y; Yin L
    Adv Mater; 2022 Jun; 34(23):e2109517. PubMed ID: 35388551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.